Literature DB >> 9420430

Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells.

H Naganuma1, A Sasaki, E Satoh, M Nagasaka, S Nakano, S Isoe, K Tasaka, H Nukui.   

Abstract

The effect of transforming growth factor-beta (TGF-beta) secreted by glioblastoma (T98G) cells on the secretion of interferon-gamma (IFN-gamma) by lymphokine-activated killer (LAK) cells stimulated with tumor cells was investigated in cocultures of LAK and Daudi cells supplemented with T98G culture supernatant, T98G culture supernatant preincubated with anti-TGF-beta 1 and anti-TGF-beta 2 neutralizing antibodies, anti-TGF-beta 1 and anti-TGF-beta 2 antibodies, or natural human TGF-beta 1 or recombinant human TGF-beta 2. LAK cells were incubated with anti-TGF-beta 1 and anti-TGF-beta 2 antibodies, and with T98G cells of which the supernatant contained both active and latent forms of TGF-beta 1 and TGF-beta 2, with or without neutralizing antibodies. Addition of the supernatant from T98G cells to LAK/Daudi culture caused inhibition of IFN-gamma secretion by LAK cells. The inhibition was abolished by pretreatment of the supernatants with anti-TGF-beta antibodies. Addition of TGF-beta 1 and TGF-beta 2 to the LAK/Daudi culture inhibited IFN-gamma secretion by LAK cells in a dose-dependent manner. Addition of anti-TGF-beta antibodies to the LAK culture resulted in increased IFN-gamma secretion. T98G cells failed to stimulate LAK cells to secrete more IFN-gamma. Addition of anti-TGF-beta antibodies to the LAK-T98G culture resulted in increased IFN-gamma secretion by LAK cells. These results suggest that most malignant glioma cells which secrete high levels of TGF-beta can inhibit IFN-gamma secretion by LAK cells even after tumor cell stimulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9420430     DOI: 10.2176/nmc.36.789

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  8 in total

1.  Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

Authors:  Neil Senzer; Minal Barve; Joseph Kuhn; Anton Melnyk; Peter Beitsch; Martin Lazar; Samuel Lifshitz; Mitchell Magee; Jonathan Oh; Susan W Mill; Cynthia Bedell; Candice Higgs; Padmasini Kumar; Yang Yu; Fabienne Norvell; Connor Phalon; Nicolas Taquet; Donald D Rao; Zhaohui Wang; Chris M Jay; Beena O Pappen; Gladice Wallraven; F Charles Brunicardi; David M Shanahan; Phillip B Maples; John Nemunaitis
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

2.  Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells.

Authors:  Hirofumi Naganuma; Eiji Satoh; Takayuki Asahara; Kenichi Amagasaki; Arata Watanabe; Hiroki Satoh; Katsuhiro Kuroda; Lei Zhang; Hideaki Nukui
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

Review 3.  Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.

Authors:  Ze-Long Liu; Jing-Hua Liu; Daniel Staiculescu; Jiang Chen
Journal:  Ther Adv Med Oncol       Date:  2021-05-24       Impact factor: 8.168

4.  Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.

Authors:  So Young Kim; Dongxu Kang; Hye Jin Choi; Yeonsoo Joo; Joo-Hang Kim; Jae J Song
Journal:  Oncotarget       Date:  2017-02-28

Review 5.  STATs in NK-Cells: The Good, the Bad, and the Ugly.

Authors:  Dagmar Gotthardt; Veronika Sexl
Journal:  Front Immunol       Date:  2017-01-18       Impact factor: 7.561

Review 6.  Targeting TGFβ signal transduction for cancer therapy.

Authors:  Sijia Liu; Jiang Ren; Peter Ten Dijke
Journal:  Signal Transduct Target Ther       Date:  2021-01-08

7.  Expression of endometrial immune-related genes possibly functioning during early pregnancy in the mare.

Authors:  Yurika Tachibana; Yasuko Nakano; Kentaro Nagaoka; Masato Kikuchi; Yasuo Nambo; Shingo Haneda; Motozumi Matsui; Yo-Ichi Miyake; Kazuhiko Imakawa
Journal:  J Reprod Dev       Date:  2012-11-09       Impact factor: 2.214

8.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Reva Schneider; Robert Mennel; Carl Lenarsky; Gladice Wallraven; Beena O Pappen; John LaNoue; Padmasini Kumar; Derek Nemunaitis; Alyssa Roth; James Nemunaitis; Sam Whiting; Neil Senzer; Frederick A Fletcher; John Nemunaitis
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.